Pharmaceutical composition for treating cardiovascular disease and preparation method thereof

A composition and cardiovascular technology are applied in the field of pharmaceutical compositions for the treatment of cardiovascular diseases, pharmaceutical compositions for the treatment of cardiovascular diseases and their preparation fields, which can solve the problems of complex components of the compound formula, and achieve the reduction of myocardial infarction, the reduction of content, The effect of reducing myocardial infarction size

Active Publication Date: 2013-06-19
HEHUANG PHARMA SHANGHAI +1
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the complexity of the compound ingredients, its medicinal components a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating cardiovascular disease and preparation method thereof
  • Pharmaceutical composition for treating cardiovascular disease and preparation method thereof
  • Pharmaceutical composition for treating cardiovascular disease and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Take the following ingredients to form the pharmaceutical composition of the present invention: Japanese bufatalin, ginsenoside Re, ginsenoside Ra 1 , 1β-hydroxybufalin, ginsenoside Rb 1 , Recibuadin Alcohol, Ginsenoside Rc, Ginsenoside Rb 2 , Ginsenosides, Ginsenoside Rd, Bufalin, Cholic Acid, Hyodeoxycholic Acid, Cinobufinyl, Chenodeoxycholic Acid, and Deoxycholic Acid.

[0043] Prepare 1000 formulation units.

[0044] Preparation method: mix the above compound and auxiliary materials, and prepare tablets, dispersible tablets, buccal tablets, orally disintegrating tablets, sustained-release tablets, capsules, soft capsules, dropping pills, granules, injections, etc. according to conventional methods.

[0045] in,

[0046] japonica bufatalin 1.0 mg (the preparation process is as follows: toad bufa medicinal material coarse powder (20 mesh), percolation with 95% ethanol ethanol, the residue is reflux extracted with 70% ethanol, the combined extracts are concentrated ...

Embodiment 2

[0063] Take the following components by weight ratio to form the pharmaceutical composition of the present invention: bufatalin japonica 5 mg, ginsenoside Re 10.0 mg, ginsenoside Ra 1 10.0mg, 1β-hydroxybufalin 5mg, ginsenoside Rb 1 10.0mg, reciprocin 10.0mg, ginsenoside Rc 10.0mg, ginsenoside Rb 2 10.0mg, Ginsenoside Rb 3 10.0mg, ginsenoside Rd 10.0mg, bufalin 1.5mg, cholic acid 10.0mg, hyodeoxycholic acid 10.0mg, cinobufaction base 2.5mg, chenodeoxycholic acid 10.0mg, deoxycholic acid 10.0mg. Prepare 1000 formulation units.

[0064] Preparation method: mix the above compound and auxiliary materials, and prepare tablets, dispersible tablets, buccal tablets, orally disintegrating tablets, sustained-release tablets, capsules, soft capsules, dropping pills, granules, injections, etc. according to conventional methods.

[0065] Wherein each component preparation method and source are with embodiment 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to a field of medicament preparation, and relates to a pharmaceutical composition for treating cardiovascular disease and a preparation method thereof, especially to the pharmaceutical composition which contains drug-efficacy component groups capable of being absorbed into blood. The drug-efficacy component groups comprise: Japanese bufotaline, ginsenoside Re, ginsenoside Ra1, 1[beta]-hydroxy bufalin, ginsenoside Rb1, resibufogenin fine alcohol, ginsenoside Rc, ginsenoside Rb2, ginsenoside, ginsenoside Rd, bufalin, cholic acid, hyodeoxy cholic acid, cinobufagin, chenodeoxycholic acid and deoxycholic acid. The medicament has clear in vivo targets, has characteristics and advantages of multi-component multi-target effects, is good in protective effects for acute myocardial ischemia, and can reduce area of myocardial infarction and content of Lactate dehydrogenase and creatine kinase in serum.

Description

technical field [0001] The invention belongs to the field of medicine preparation, and relates to a medicine composition for treating cardiovascular diseases and a preparation method thereof. In particular, it relates to a pharmaceutical composition for treating cardiovascular diseases containing a group of medicinal components that can be absorbed into the blood. Background technique [0002] Cardiovascular disease is the number one killer of human health, and its incidence rate remains high all the time. In my country, with the continuous improvement of living standards and the increase of life pressure, the incidence of cardiovascular disease has been on the rise. [0003] The causes of cardiovascular disease include long-term smoking, high blood pressure, high blood fat, high blood sugar, and long-term external environmental stress. With the deepening of research, people gradually realize that the pathogenesis of cardiovascular disease is very complex and a dynamic pro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61K31/585A61K31/575A61K31/185A61P9/00A61P9/10
Inventor 詹常森张卫东周俊杰柳润辉陈忠樑姜鹏徐瑞林张正光
Owner HEHUANG PHARMA SHANGHAI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap